Donate
Australian & New Zealand Childrens Haematology/Oncology Group

ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
A pilot study to test the feasibility and safety and efficacy of the addition of the BiTE antibody Blinatumomab to the Interfant-06 backbone in infants with MLL-rearranged acute lymphoblastic leukemia (A collaborative study of the Interfant network)
Protocol ID
NL59901.078.17 (BlinFant)
Disease (Sub Disease)
Leukaemia(ALL)
Diagnosis Stage
New diagnosis
Location
NSW, QLD, VIC
Sponsor
Australian and New Zealand Children's Haematology Oncology Group
Princess Maxima Center for Pediatric Oncology & Utrecht
Trial Status
Open
Sites
The Children's Hospital at Westmead
Queensland Children's Hospital
Royal Children's Hospital
Study Type
Treatment
Phase
Pilot
Age Eligibility
<12 months
ANZCTR
ACTRN12620000542998
Back to Registry
Study Title A pilot study to test the feasibility and safety and efficacy of the addition of the BiTE antibody Blinatumomab to the Interfant-06 backbone in infants with MLL-rearranged acute lymphoblastic leukemia (A collaborative study of the Interfant network)
Protocol ID NL59901.078.17 (BlinFant)
Disease (Sub Disease) Leukaemia(ALL)
Diagnosis Stage New diagnosis
Location NSW / QLD / VIC
Sponsor Australian and New Zealand Children's Haematology Oncology Group/ Princess Maxima Center for Pediatric Oncology & Utrecht
Links https://anzctr.org.au/Trial/Registration/TrialReview.aspx?id=379482&isReview=true
Trial Status Open
Trial Open Date 20/07/2018
Sites The Children's Hospital at Westmead / Queensland Children's Hospital / Royal Children's Hospital
Study Type Treatment
Phase Pilot
Age Eligibility <12 months
ANZCTR ACTRN12620000542998